Who are the applicable groups of Larotinib/Larotinib?

Larotrectinib is an antineoplastic agent and a tropomyosin receptor kinase (TRK) A, TRK B and TRK A potent and selective inhibitor of C, it is indicated for the treatment of solid tumors containing neurotrophic receptor tyrosine kinase (NTRK) gene fusions, particularly solid tumors containing NTRK fusion proteins (without known acquired resistance mutations) in patients with metastatic disease or in patients who are at risk for severe morbidity after surgical resection and whose disease has progressed after prior treatment or who are ineligible for other treatment options (the U.S. Food and Drug Administration [FDA] has orphan drug designation for these cancers).

Before initiating treatment, it is necessary to confirm the presence of NTRK fusions using an FDA-approved diagnostic test. International experts recommend considering treatment with selective TRK inhibitors (such as entrectinib, larotrectinib) in adult patients with TRK fusion-positive cancers, including radioactive iodine-refractory thyroid cancer, colorectal cancer (which may also be considered in the first line if alternative treatments are not suitable), non-small cell lung cancer, soft tissue sarcoma, salivary gland cancer and other TRK fusion-positive cancers for which there are no other effective or suitable treatment options.

International experts pointed out that becauseNTRK gene fusion is a characteristic manifestation of infantile fibrosarcoma, selective TRK inhibitors should be considered as first-line systemic therapy for patients with unresectable or metastatic infantile fibrosarcoma. Pediatric patients with other TRK fusion-positive cancers may also be considered, including unresectable/metastatic non-rhabdomyosarcoma soft tissue sarcoma, differentiated thyroid cancer (if standard treatments are ineffective or inappropriate), unresectable/metastatic glioma, and other TRK fusion-positive cancers for which there are no other effective or appropriate treatment options.